May 31st 2022

CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern

CARE paper published in Antiviral Research: Insight on the activity of Remdesivir, Molnupiravir and Nirmatrelvir on SARS-CoV-2 variants of concern

The CARE partner KU Leuven, in collaboration with University Hospitals Leuven evaluated the susceptibility of SARS-CoV-2 variants   to Remdesivir, Molnupiravir and Nirmatrelvir. The three molecules have in vitro antiviral activities against the ancestral virus as well as the alpha, beta, gamma, delta and omicron variants. This indicates that the target genes of these antivirals are highly conserved between SARS-CoV-2 variants.

To learn more, read the paper in Antiviral Research: Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern